AgomAb Therapeutics NV (AGMB) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 2, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed Apr 23, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the AGMB SEC filings page.
This page shows AgomAb Therapeutics NV (AGMB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. All figures are derived from SEC filings (20-F and 6-K reports).
Financial Health Signals
We do not publish a peer-relative financial health score for AgomAb Therapeutics NV, because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
AgomAb Therapeutics NV reported a net loss of $73.4M while operations used $60.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.
AgomAb Therapeutics NV reported an operating loss of $69.6M against $70K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
AgomAb Therapeutics NV's EBITDA was -$69.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
AgomAb Therapeutics NV reported a net loss of $73.4M in fiscal year 2025.
AgomAb Therapeutics NV earned -$168.08 per diluted share (EPS) in fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
AgomAb Therapeutics NV held $101.4M in cash as of fiscal year 2025; no long-term debt figure is on record for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
AgomAb Therapeutics NV's ROE was -47.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
AgomAb Therapeutics NV invested $57.4M in research and development in fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
AGMB Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F |
|---|---|
| R&D Expenses | $57.4M |
| Operating Income | -$69.6M |
| EBITDA | -$69.3M |
| Interest Expense | $70K |
| Net Income | -$73.4M |
| EPS (Basic) | -$168.08 |
| EPS (Diluted) | -$168.08 |
| Diluted Shares (Avg) | 541,126 |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, SG&A Expenses, Income Tax.
AGMB Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F |
|---|---|
| Total Assets | $180.4M |
| Current Assets | $142.3M |
| Cash & Equivalents | $101.4M |
| Goodwill | $10.1M |
| Total Liabilities | $26.8M |
| Current Liabilities | $21.8M |
| Non-Current Liabilities | $4.9M |
| Total Equity | $153.6M |
Not reported in any period shown, so not listed: Short-Term Investments, Inventory, Accounts Receivable, Long-Term Investments, Long-Term Debt, Retained Earnings.
AGMB Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F |
|---|---|
| Operating Cash Flow | -$60.7M |
| Depreciation & Amortization | $257K |
| Investing Cash Flow | -$38.7M |
| Financing Cash Flow | -$397K |
Not reported in any period shown, so not listed: Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
AGMB Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F |
|---|---|
| Return on Equity | -47.8% |
| Return on Assets | -40.7% |
| Current Ratio | 6.52 |
| Liabilities-to-Equity | 0.17 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| AgomAb Therapeutics NV AGMB | FY2025 | N/A | -$73.4M | N/A | $330.9M | — |
| Contineum Therapeutics, Inc. CTNM | FY2025 | N/A | -$60.0M | N/A | $359.7M | — |
| Zura Bio Limited ZURA | FY2025 | N/A | -$68.7M | N/A | $379.5M | — |
| Tectonic Therapeutic, Inc. TECX | FY2025 | N/A | -$74.2M | N/A | $371.0M | — |
| Avalo Therapeutics, Inc. AVTX | FY2025 | $59K | -$78.3M | N/A | $392.6M | — |
| Relmada Therapeutics, Inc. RLMD | FY2025 | N/A | -$57.4M | N/A | $409.6M | — |
Where AgomAb Therapeutics NV Ranks
Frequently Asked Questions
No, AgomAb Therapeutics NV (AGMB) reported a net loss of $73.4M in fiscal year 2025.
AgomAb Therapeutics NV (AGMB) had EBITDA of -$69.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
AgomAb Therapeutics NV (AGMB) has a return on equity of -47.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
AgomAb Therapeutics NV (AGMB) recorded an outflow of $60.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
AgomAb Therapeutics NV (AGMB) had $180.4M in total assets as of fiscal year 2025, including both current and long-term assets.
AgomAb Therapeutics NV (AGMB) invested $57.4M in research and development during fiscal year 2025.
AgomAb Therapeutics NV (AGMB) had a current ratio of 6.52 as of fiscal year 2025, which is generally considered healthy.
AgomAb Therapeutics NV (AGMB) had a liabilities-to-equity ratio of 0.17 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
AgomAb Therapeutics NV (AGMB) had a return on assets of -40.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
AgomAb Therapeutics NV (AGMB) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $330.9M as of Nov 2, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
AgomAb Therapeutics NV (AGMB) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $330.9M as of Nov 2, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
AgomAb Therapeutics NV (AGMB) reported a net loss of $73.4M while operations used $60.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
AgomAb Therapeutics NV (AGMB) reported an operating loss of $69.6M against $70K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.